Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ultragenyx Pharmaceu
(NQ:
RARE
)
48.73
-0.36 (-0.73%)
Streaming Delayed Price
Updated: 11:15 AM EST, Dec 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ultragenyx Pharmaceu
< Previous
1
2
3
4
5
Next >
Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
November 06, 2024
Via
Benzinga
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast
November 04, 2024
Via
Benzinga
Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical
October 21, 2024
Via
Benzinga
Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views
September 20, 2024
Via
Benzinga
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
August 06, 2024
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
3 Genomics Stocks That May Transform Personalized Medicine
August 06, 2024
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry.
Via
InvestorPlace
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
July 22, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
May 31, 2024
Via
Benzinga
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
April 22, 2024
Via
Benzinga
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
July 22, 2024
Biogen previously decided against opting into Ionis' Angelman program.
Via
Investor's Business Daily
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts
April 05, 2024
Via
Benzinga
Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 13, 2024
Via
Benzinga
This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
June 06, 2024
Via
Benzinga
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
May 22, 2024
The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024
May 02, 2024
RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
April 15, 2024
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
March 18, 2024
Via
Benzinga
Recap: Ultragenyx Pharmaceutical Q4 Earnings
February 15, 2024
Via
Benzinga
The Latest Analyst Ratings For Ultragenyx Pharmaceutical
February 15, 2024
Via
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...
Via
Benzinga
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
April 15, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Preview: Ultragenyx Pharmaceutical's Earnings
February 14, 2024
Via
Benzinga
4 Analysts Have This To Say About Ultragenyx Pharmaceutical
January 19, 2024
Via
Benzinga
Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
April 15, 2024
New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data.
Via
Benzinga
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
April 15, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
January 18, 2024
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.